Role of Immunotherapy in Patients with NSCLC: Emerging Biomarkers

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, give an overview of the role of molecular biomarkers in the non–small cell lung cancer treatment space.

Expert oncologists discuss barriers to molecular testing and the use of liquid biopsy in non–small cell lung cancer.

An overview of the prevalence of molecular biomarkers in NSCLC and their effect on treatment decisions.

Martin Dietrich, MD, PhD, describes his approach to using anti-PD-1 therapies in non–small cell lung cancer.

Meghan J. Mooradian, MD, discusses how she makes NSCLC treatment decisions based on concurrent mutations.

Takeaways from the CheckMate 9LA, CheckMate 227, and POSEIDON trials focused on immunotherapy in non–small cell lung cancer.

Meghan J. Mooradian, MD, shares her approach to communicating with patients with NSCLC regarding treatment decisions based on molecular biomarkers.

Expert oncologists look to the future of the NSCLC treatment landscape and discuss unmet needs and promising therapies.

Martin Dietrich, MD, PhD, and Meghan J. Mooradian, MD, conclude their discussion by discussing how they address treatment toxicity in NSCLC.